# Johnson & Johnson (jnj)

Generated: `2026-02-03T11:03:52Z`

## KPIs

- Assets: **45**
- Assets with linked trials: **11**
- Trials: **196**

### Assets by stage
- Phase 3: **18**
- Phase 1: **14**
- Registrationion: **7**
- Phase 2: **6**

### Trials by status
- RECRUITING: **103**
- ACTIVE_NOT_RECRUITING: **81**
- NOT_YET_RECRUITING: **12**

## Top assets

| Asset | Highest stage | Linked trials | Example indications |
|---|---:|---:|---|
| TREMFYA | Phase 3 | 23 | Pediatric Ulcerative; Pediatric Ulcerative; Pediatric Ulcerative |
| system) RYBREVANT | Phase 3 | 22 | Frontline Non Small; Frontline Non Small; Frontline Non Small |
| ERLEADA | Phase 3 | 20 | ASCT Localized Prostate; ASCT Localized Prostate; ASCT Localized Prostate |
| nipocalimab​ | Phase 3 | 10 | Hemolytic Disease; Hemolytic Disease; Hemolytic Disease |
| bleximenib | Phase 3 | 4 | Relapsed Refractory 1); Relapsed Refractory 1); Relapsed Refractory 1) |
| SPRAVATO | Phase 3 | 1 | Major Depressive Disorder Pediatrics; Major Depressive Disorder Pediatrics; Major Depressive Disorder Pediatrics |
| TALVEY + TECVAYLI | Phase 3 | 0 | Relapsed Refractory; Relapsed Refractory; Relapsed Refractory |
| system) INLEXZO (gemcitabine | Phase 3 | 0 | High Risk High Risk Non Muscle; High Risk High Risk Non Muscle; High Risk High Risk Non Muscle |
| S I R T U R O | Phase 3 | 0 | L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen; L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen; L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen |
| RYBREVANT | Phase 3 | 0 | Colorectal Cancer; Colorectal Cancer; Colorectal Cancer |
| MorphoSys AG; JNJ-2113: Protagonist Therapeutics; | Phase 3 | 0 | and Memorial Sload Kettering; CARVYKTI: Legend XmAb CD28 bispecific antibodies; Xencor;; and Memorial Sload Kettering; CARVYKTI: Legend XmAb CD28 bispecific antibodies; Xencor;; and Memorial Sload Kettering; CARVYKTI: Legend XmAb CD28 bispecific antibodies; Xencor; |
| JNJ-7446 | Phase 3 | 0 | Lung Cancer; Lung Cancer; Lung Cancer |
| JNJ-4804 Co-antibody | Phase 3 | 0 | Psoriatic Arthritis; Psoriatic Arthritis; Psoriatic Arthritis |
| JNJ-4681 | Phase 3 | 0 | Hematological Malignancies; Hematological Malignancies; Hematological Malignancies |
| JNJ-2175 | Phase 3 | 0 | Solid Tumors; Solid Tumors; Solid Tumors |
| JNJ-1887​ sCD59 | Phase 3 | 0 | Geographic Atrophy; Geographic Atrophy; Geographic Atrophy |
| ITI-1284 | Phase 3 | 0 | Alzheimer's Disease-Related; Alzheimer's Disease-Related; Alzheimer's Disease-Related |
| Bleximenib | Phase 3 | 0 | Newly Diagnosed AML, with Venetoclax and; Newly Diagnosed AML, with Venetoclax and; Newly Diagnosed AML, with Venetoclax and |
| UCL Business Plc; JNJ-1887: Hemera Biosciences; | Phase 2 | 0 | and Mitsubishi Tanabe Pharma Corporation; TREMFYA: Genmab A/S; ERLEADA: Regents of California Genmab A/S; ENHANZE platform; Halozyme Therapeutics;; and Mitsubishi Tanabe Pharma Corporation; TREMFYA: Genmab A/S; ERLEADA: Regents of California Genmab A/S; ENHANZE platform; Halozyme Therapeutics;; and Mitsubishi Tanabe Pharma Corporation; TREMFYA: Genmab A/S; ERLEADA: Regents of California Genmab A/S; ENHANZE platform; Halozyme Therapeutics; |
| intravesical delivery | Phase 2 | 0 | Bladder Cancer BCG-naïve; Bladder Cancer BCG-naïve; Bladder Cancer BCG-naïve |
| Indications | Phase 2 | 0 | for Major Depressive Disorder; for Major Depressive Disorder; for Major Depressive Disorder |
| Colitis | Phase 2 | 0 | Psoriatic Arthritis; Psoriatic Arthritis; Psoriatic Arthritis |
| autoleucel) | Phase 2 | 0 | Myeloma Transplant Eligible vs; Myeloma Transplant Eligible vs; Myeloma Transplant Eligible vs |
| a c t o r X l a ) | Phase 2 | 0 | i o n through clinical trials as well as those to the best of the Company's knowledge. Johnson; i o n through clinical trials as well as those to the best of the Company's knowledge. Johnson; i o n through clinical trials as well as those to the best of the Company's knowledge. Johnson |
| TECVAYLI | Phase 1 | 30 | Multiple Myeloma; Multiple Myeloma; Multiple Myeloma |

## Recent changes

- `` **trials_ingested** — {"trials_seen": 196, "inserted": 196, "updated": 0, "status_changed": 0, "bad_aliases": 2}
- `` **trials_ingested** — {"trials_seen": 196, "inserted": 0, "updated": 196, "status_changed": 0, "bad_aliases": 2}
- `` **trials_ingested** — {"trials_seen": 196, "inserted": 0, "updated": 196, "status_changed": 0, "bad_aliases": 2}
- `` **trial_assets_linked** — {"nct_id": "NCT05972135", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT06285318", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT06208150", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT04267887", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05818683", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05901649", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05884398", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT04557059", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT03523442", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT03767244", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT04108208", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT04325828", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT04662580", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT07002320", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05960578", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT06274047", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT04181203", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT06067269", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT02913196", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT03903835", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT03902951", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT03141671", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT03899077", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT03466411", "linked_assets": 2}
- `` **trial_assets_linked** — {"nct_id": "NCT03218488", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT06934226", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05092269", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT04372108", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05083182", "linked_assets": 2}
- `` **trial_assets_linked** — {"nct_id": "NCT06807593", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT03941132", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05299931", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT02103361", "linked_assets": 2}
- `` **trial_assets_linked** — {"nct_id": "NCT05387031", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT04496063", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT04033445", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT03451851", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT06663332", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05242471", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05049798", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT07141004", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT04929210", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT06408935", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05347095", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05242484", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT05923073", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT04936308", "linked_assets": 1}

## Trials (latest)

| NCT | Status | Phase | Last update | Linked assets |
|---|---|---|---|---|
| NCT03466411 | ACTIVE_NOT_RECRUITING | PHASE2,PHASE3 | 2026-02-02 | STELARA; TREMFYA |
| NCT04033445 | ACTIVE_NOT_RECRUITING | PHASE2,PHASE3 | 2026-02-02 | TREMFYA |
| NCT03451851 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-02-02 | TREMFYA |
| NCT03596645 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-02-02 |  |
| NCT06266663 | RECRUITING |  | 2026-02-02 |  |
| NCT03901963 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-02-02 |  |
| NCT03462719 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-02-02 |  |
| NCT03390504 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-02-02 |  |
| NCT05388669 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-02-02 |  |
| NCT02365597 | ACTIVE_NOT_RECRUITING | PHASE2 | 2026-01-30 |  |
| NCT03301220 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-01-30 |  |
| NCT03881098 | RECRUITING | NA | 2026-01-29 |  |
| NCT05421663 | RECRUITING | PHASE1,PHASE2 | 2026-01-27 |  |
| NCT04557098 | ACTIVE_NOT_RECRUITING | PHASE2 | 2026-01-27 | TECVAYLI |
| NCT06319820 | RECRUITING | PHASE3 | 2026-01-27 |  |
| NCT05289687 | RECRUITING | PHASE2 | 2026-01-26 |  |
| NCT07245394 | RECRUITING |  | 2026-01-23 |  |
| NCT06193863 | ACTIVE_NOT_RECRUITING |  | 2026-01-23 |  |
| NCT05316155 | RECRUITING | PHASE1,PHASE2 | 2026-01-22 |  |
| NCT05900388 | NOT_YET_RECRUITING |  | 2026-01-21 |  |
| NCT05601973 | ACTIVE_NOT_RECRUITING | PHASE2 | 2026-01-21 | system) RYBREVANT |
| NCT05972135 | RECRUITING | PHASE2 | 2026-01-20 | TECVAYLI |
| NCT04267887 | ACTIVE_NOT_RECRUITING | PHASE2 | 2026-01-20 | ERLEADA |
| NCT06285318 | RECRUITING |  | 2026-01-16 | TECVAYLI |
| NCT06208150 | RECRUITING | PHASE3 | 2026-01-16 | TECVAYLI |
| NCT04892173 | RECRUITING | PHASE3 | 2026-01-16 |  |
| NCT07219212 | RECRUITING | PHASE1 | 2026-01-16 |  |
| NCT05818683 | RECRUITING | PHASE1 | 2026-01-16 | ERLEADA |
| NCT05901649 | ACTIVE_NOT_RECRUITING |  | 2026-01-16 | ERLEADA |
| NCT05884398 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-01-16 | ERLEADA |
| NCT04557059 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-01-16 | ERLEADA |
| NCT03523442 | ACTIVE_NOT_RECRUITING | PHASE1 | 2026-01-16 | ERLEADA |
| NCT03767244 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-01-16 | ERLEADA |
| NCT03218488 | ACTIVE_NOT_RECRUITING |  | 2026-01-16 | STELARA |
| NCT00508547 | ACTIVE_NOT_RECRUITING |  | 2026-01-16 |  |
| NCT06934226 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-01-16 | STELARA |
| NCT05092269 | RECRUITING | PHASE3 | 2026-01-16 | STELARA |
| NCT04372108 | RECRUITING |  | 2026-01-16 | STELARA |
| NCT07242248 | RECRUITING |  | 2026-01-16 |  |
| NCT06663332 | RECRUITING | PHASE3 | 2026-01-16 | TREMFYA |
| NCT05242471 | ACTIVE_NOT_RECRUITING | PHASE2 | 2026-01-16 | TREMFYA |
| NCT05049798 | ACTIVE_NOT_RECRUITING |  | 2026-01-16 | TREMFYA |
| NCT07141004 | RECRUITING | PHASE4 | 2026-01-16 | TREMFYA |
| NCT04929210 | RECRUITING | PHASE4 | 2026-01-16 | TREMFYA |
| NCT07102368 | RECRUITING |  | 2026-01-16 |  |
| NCT06408935 | RECRUITING | PHASE3 | 2026-01-16 | TREMFYA |
| NCT05347095 | ACTIVE_NOT_RECRUITING | PHASE3 | 2026-01-16 | TREMFYA |
| NCT07220824 | RECRUITING |  | 2026-01-16 |  |
| NCT05242484 | ACTIVE_NOT_RECRUITING | PHASE2 | 2026-01-16 | TREMFYA |
| NCT06260163 | RECRUITING | PHASE3 | 2026-01-16 |  |
